Welcome to our dedicated page for MINIMED GROUP SEC filings (Ticker: MMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MINIMED GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MINIMED GROUP's regulatory disclosures and financial reporting.
MiniMed Group, Inc. director D Keith Grossman reported an equity compensation grant of 13,889 shares of Common Stock on March 9, 2026. The award consists of restricted stock units that vest on the one-year anniversary of the grant date and were granted at no cash cost to him.
Following this grant, Grossman holds 13,889 shares of Common Stock directly, including shares that will be issued upon vesting of one or more restricted stock units. This filing reflects a compensation-related acquisition rather than an open-market stock purchase.
EISENBERG GLENN A reported acquisition or exercise transactions in this Form 4 filing.
MiniMed Group, Inc. director Glenn A. Eisenberg received an equity grant of 13,889 shares of common stock in the form of restricted stock units. The units were awarded at no cash cost and vest on the one-year anniversary of the grant date. Following this award, he directly holds 13,889 shares and units, including shares to be issued upon future vesting of restricted stock units.
MiniMed Group, Inc. director Kevin E. Lofton reported an equity compensation grant of 27,778 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and is scheduled to vest on the one-year anniversary of the grant date.
After this grant, Lofton is shown as owning 27,778 shares directly, which include shares to be issued upon future vesting of one or more restricted stock units. This filing reflects a routine compensation-related acquisition rather than an open-market purchase or sale.
MiniMed Group, Inc. officer John Gyurci reported equity compensation grants on March 9, 2026. He received 2,778 performance-based restricted stock units, each tied to one share of common stock, which vest on March 9, 2027 only if MMED’s closing price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement. He was also granted options on 25,253 shares of common stock at an exercise price of $18.00 per share, expiring on March 9, 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.
MiniMed Group, Inc. officer Chandrasena Gillian reported compensation-related equity awards, not open-market trades. She received 6,945 performance-based restricted stock units, each representing a right to one MMED common share, which vest on March 9, 2027 if MMED’s closing share price is at least $32.05 as of the defined Divestment Date.
She also received employee stock options for 63,132 MMED common shares at an exercise price of $18.00 per share, expiring in 2036. These options vest 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030. All holdings reported are owned directly.
MiniMed Group, Inc. insider Courtney Nelson received new equity awards as compensation. On March 9, 2026, Nelson was granted 6,945 performance-based restricted stock units, each tied to one share of MMED common stock. These units vest on March 9, 2027 if MMED’s closing share price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement.
On the same date, Nelson also received an option to purchase 63,132 shares of MMED common stock at an exercise price of $18.00 per share, expiring March 9, 2036. This option vests 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030. All awards are reported as directly owned and are grants, not open-market purchases or sales.
MiniMed Group, Inc. reported that officer Ali Dianaty received equity-based compensation. On March 9, 2026, Dianaty was granted 13,889 performance-based RSUs, each tied to one share of MMED common stock and vesting around March 9, 2027 based on share-price performance and a divestment-related date defined in a March 1, 2026 separation agreement. On the same date, Dianaty also received 126,263 stock options with a $18.00 exercise price, expiring in 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030. All holdings reported are direct and reflect compensation grants rather than open-market purchases or sales.
MiniMed Group, Inc. reported that EVP and Chief Financial Officer Chad Spooner received new equity awards. He was granted 27,778 performance-based restricted stock units, each representing one share of common stock, vesting on March 9, 2027, if MiniMed’s share price reaches at least $32.05 as of the Divestment Date. He also received options for 84,176 shares of common stock at an exercise price of $18.00 per share, vesting 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030, with expiration on March 9, 2036.
MiniMed Group, Inc. Chief Executive Officer Dallara Que reported awards of new equity-based compensation. On March 9, 2026, Que received 83,334 performance-based restricted stock units, each representing a contingent right to one share of MiniMed common stock. These units vest on March 9, 2027 if MiniMed’s common stock closes at or above $32.05 per share as of the defined Divestment Date.
On the same date, Que also received 252,526 employee stock options with an exercise price of $18.00 per share and expiration on March 9, 2036. These options vest in tranches of 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030, providing a long-term incentive structure tied to future service and share price performance.
MiniMed Group, Inc. completed its initial public offering of 28,000,000 shares of common stock at $20.00 per share, generating net proceeds of approximately $538 million. The company retained $309 million, resulting in approximately $350 million of cash on hand, and used the remainder to repay intercompany debt owed to Medtronic.
MiniMed was separated from Medtronic’s Diabetes business, with Medtronic now owning approximately 90.03% of outstanding shares. The company established a $500 million five-year senior secured revolving credit facility for working capital and general corporate purposes, reconstituted its board and committees, and adopted new equity, incentive, deferred compensation, and retirement plans for directors and executives.